We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Links Uncovered Between Psychotic Experiences

By LabMedica International staff writers
Posted on 09 Oct 2019
Psychotic experiences, such as hallucinations and delusions, are features of psychiatric disorders, such as schizophrenia, but they are also reported by approximately 5% to 10% of the general population.

Studying the genetic causes of psychotic experiences in the general population, and its association with the genetic causes of other disorders, may increase the understanding of their pathologic significance. More...
There are shared genetic connections between psychotic experiences and conditions on the psychotic spectrum like schizophrenia, but also with conditions like major depressive disorder and autism spectrum disorder.

A team of scientists working with Cardiff University (Cardiff, UK) analyzed data from the UK Biobank to tease out whether the genetic liability for having a psychotic experience overlaps with that of neuropsychiatric diseases. The team included in their analysis individuals diagnosed with a neuropsychiatric condition, and they had a sample of 7,803 individuals who reported experiencing at least one psychotic experience. The 147,461 individuals who reported no such experience served as the control group.

Through a genome-wide association (GWAS) study of any psychotic experience, the scientists identified two variants, an intronic variant in Ankyrin-3 (ANK3) and an intergenic variant rs10994278. ANK3 encodes ankyrin-G, a protein that regulates the assembly of voltage-gated sodium channels and is needed for normal synaptic function. ANK3, the team noted, has also been tied to bipolar disorder. A second GWAS limited to the 2,143 individuals who rated their psychotic experiences to be distressing identified two additional variants, one in an intron of cannabinoid receptor 2 (CNR2) and an intergenic variant rs3849810. CNR2 encodes CB2, one of the two well-known cannabinoid receptors. A third GWAS of the 3,337 individuals who reported multiple psychotic experiences did not turn up any additional loci.

The authors concluded that in the largest GWAS of psychotic experiences from the population-based UK Biobank sample, they found support for a shared genetic liability between psychotic experiences and several psychiatric disorders including schizophrenia, major depressive disorder, bipolar disorder, and neurodevelopmental disorders, indicating that psychotic experiences are not specifically associated with schizophrenia, but rather with a general risk for mental health disorders. The study was published September 25, 2019, in the journal JAMA Psychiatry.

Related Links:
Cardiff University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.